Zogenix, Inc. (ZGNX)
ZGNXPrice: $26.68
Fair Value: 🔒
🔒score
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical t... more
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the l... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Stephen Farr |
| IPO Date | 2010-11-23 | CAGR | — |
| Employees | 327 | Website | www.zogenix.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ZGNX chart loading...
Fundamentals
Technicals
| Enterprise Value | $977.35M | P/E Ratio | -6.56 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 8 |
| P/CF Ratio | -7.73 | P/FCF Ratio | — |
| EPS | $-4.07 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 498.78% | Gross Margin | 0.94% |
| Operating Margin | -2.6% | Profit Margin | -2.78% |
| ROE | -0.83% | ROA | -0.49% |
| ROCE | -0.57% | Current Ratio | 3.63 |
| Quick Ratio | 3.57 | Cash Ratio | 1.04 |
| Debt/Equity | 0.94 | Interest Coverage | -13.88 |
| Altman Z Score | — | Piotroski Score | — |